Satellite cells are the main source of myogenic progenitors in postnatal skeletal muscle, but their use in cell therapy for muscle disorders is limited because these cells cannot be delivered through circulation and they are rapidly exhausted in severe myopathies. The search for alternative donor cells is ongoing, but none of the candidates so far show all the features required for successful colonization and repair of diseased muscle. In this study, we show that bisperoxovanadium, a phospho-tyrosine phosphatase inhibitor, induces myogenic cells to acquire a gene expression profile and a differentiation potential consistent with the phenotype of a circulating precursors, while maintaining their myogenic potential. These effects are mediated, at least in part, by NF-B activation through the Tyr42-IB-␣ phosphorylation, as shown by the expression of the dominant negative mutant form of the p50 NF-B subunit. Moreover, when bisperoxovanadium-treated cells are injected into the femoral artery of ␣-sarcoglican null dystrophic mice, they are able to circulate and to reach muscle tissue; importantly, they contribute to muscle regeneration, as shown by the expression of ␣-sarcoglican in some fibers. Our observations indicate that bisperoxovanadium, or similar compounds, may prove very valuable to obtain and to expand, from committed cells, multipotent cell populations suitable for gene-cell therapy applications and may help to understand the molecular basis of genome reprogramming and "stem-ness."-Castaldi, L., Serra, C., Moretti, F., Messina, G., Paoletti, R., Sampaolesi, M., Torgovnick, A., Baiocchi, M., Padula, F., Pisaniello A., Molinaro, M., Cossu, G., Levrero, M., Bouché, M. Bisperoxovanadium, a phospho-tyrosine phosphatase inhibitor, reprograms myogenic cells to acquire a pluripotent, circulating phenotype. FASEB J. 21, 3573-3583 (2007) 
Muscle regeneration in case of injury or muscular diseases is guaranteed by the activation and differentiation of satellite cells (SCs), the myogenic precursors located beneath the basal lamina of individual myofibers. SCs are characterized by the expression of the transcription factors Pax7, Msx1, and, in a subset of muscles, Pax3, of the cell surface molecules CD34, M-cadherin, and c-met and of structural proteins such as desmin (for a review see ref. 1). SCs are both able to self-renew to maintain their own pool and, upon activation, to give rise to a large number of daughter myoblasts. The use of muscle SCs in cell-mediated gene therapy approaches to correct genetic diseases, such as muscular dystrophies, is, however, limited by their rapid loss after transplantation (2) . Moreover, SCs cannot cross the vessel wall, and thus systemic delivery is not possible (3) . Recently, freshly isolated and homogeneous SCs have been shown to contribute to both muscle repair and SCs compartment repopulation, when grafted into mdx mice (4) . However, SCs expansion in culture before the engraftment greatly reduces the regenerative capacity, thus limiting their use in vivo. Although SCs are the main cellular source for muscle regeneration (5), other cell populations, including bone marrow-derived cells, bone marrow or muscle derived side population (SP), mesangioblasts, or other mesodermal-derived progenitors, can activate a myogenic program (3, 6 -9) . In most cases, the number of these cells that can be isolated from adult tissues is limited, in vitro expansion is problematic, and their actual myogenic potential is variable and possibly due to fusion, rather than transdifferentiation (10, 11) .
Committed and even terminally differentiated cells, as well as established cell lines, can dedifferentiate and/or transdifferentiate upon ectopic expression of specific genes. Myoblasts can be converted into physiologically active neurons through the activation of neuronal differentiation genes (12) . Surprisingly, terminally differentiated myotubes can be induced to partially dedifferentiate by the expression of viral oncoproteins or of the homeobox protein msx1 (13, 14) . More recently, bone marrow stromal cells have been shown to differentiate, upon ectopic expression of NICD, into various cell types in vivo (15) . Thus, reprogramming of gene expression in committed cells might be exploited to develop innovative cell therapy strategies. Ideally, the differentiation program should be inhibited in a reversible manner to allow the cells to redifferentiate when placed in the right microenvironment. Pharmacological manipulation of signaling pathways and downstream transcription factors known to inhibit myogenic differentiation could be a reasonable alternative to the ectopic expression of a given gene and would ensure the reversibility by simple removal of the drug.
NF-B and AP1 transcriptional activities are known to be rapidly down-regulated when muscle cells are induced to differentiate (16) , whereas forced NF-B and/or AP1 activity inhibits myogenesis through the regulation of cyclin D1 and/or of MyoD and myogenin (17, 18) . In this study, we tested the ability of bisperoxovanadium (BpV), a protein tyrosine phosphatase (PTP) inhibitor known to activate both NF-B and AP1 signaling, to generate, from committed myoblasts, multipotent cell populations suitable for gene-cell therapy applications.
MATERIALS AND METHODS

Cell cultures
Muscle cell cultures
C2C12 cells, a mouse satellite cell-derived cell line (19) , were grown in growing medium (GM) [Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS)]; to induce differentiation, the medium was replaced with differentiation medium (DM) [DMEM supplemented with 2% horse serum (HS), as described in ref . 20] . Primary mouse satellite cells (MSC) were prepared from 1-2 wk postnatal mouse limbs as described previously (21) . The cells were grown in DMEM supplemented with 20% HS and 5% chick embryo extract (EE). To induce differentiation, the cells were shifted to DMEM supplemented with 5% HS and 1.25% EE for 3-5 days. In both cases, BpV (10 M) was added upon shifting into DM.
Hematopoietic colony assay
C2C12 cells (10 3 cells/35mm dish) were cultured in a methylcellulose medium for colony assay of murine cells (MethoCult, Stem Cell Technologies, Inc., Vancouver, Canada) and then cultured for 4 -5 days.
Coculture with cardiomyocytes
Neonatal cardiac myocytes were prepared as described previously (22); 10 4 GFP-C2C12 cells/35mm tissue culture dish were seeded on the cardiomyocytes monolayer and cultured for additional 5 days in DM.
Cell transfections and reporter gene assays
Transfection of C2C12 cells and luciferase reporter assays were performed as described previously (20) . NF-BLuc and AP1Luc were purchased from Promega (Madison, WI, USA). The pRSV-p65 expression vector was previously described (23) ; the p50⌬SP (NF-Bp50 dominant negative) was provided by Dr. P. M. Khavari (24) . Previous studies demonstrated that exogenous expression of p50⌬SP resulted in inhibition of transcriptional inducibility of the target genes by NF-B (25) .
Cell fractionation, immunoprecipitation, and immunoblotting
For cell fractionation, C2C12 cells were collected, suspended in lysis buffer (20 mM HEPES, pH 7.5, 10 mM NaCl, phosphatase and protease inhibitors), and incubated 15 min. on ice. Nuclear fractions were obtained by centrifugation. Protein concentrations of both cytoplasmic and nuclear fractions were equalized, and SDS sample buffer was added to 1ϫ final concentration. Immunoprecipitation and immunoblotting were performed as previously described (26) . The following antibodies were used: anti-p65 (Transduction Laboratories, San Jose, CA, USA), anti-PhTyr (Cell Signaling, Danvers, MA, USA), anti-IB␣, anti-PhSer-32 IB␣, antic-jun, anti-Ph-Ser-63 c-jun, and anti-p50 (clone C-19; all from Santa Cruz Biotechnology, Santa Cruz, CA, USA).
RNA preparation and reverse transcriptase-polymerase chain reaction (RT-PCR) analysis
Total RNA extraction and cDNA synthesis were done as described previously (21) . The following PCR protocol was applied for all primer sets: 95°C for 5 min, followed by 30 cycles of PCR (1 min at 95°C, 1 min at annealing temperature, 2 min at 72°C), and a final 7 min extension step at 72°C. PCR products were separated on 1% agarose gel containing ethidium bromide. The following primers were used for PCR amplifications: ␤-actin: fw ATGCCTCTGGTCGTACCACAG-GCATTG, rev TTGCTGATCCACATCTGCTGGAAGGTG (expected band 649 bp) (27) .
Histochemical and immunofluorescence analyses
Alkaline phosphatase (ALP) or tartrate-resistant acid phosphatase (TRAP) activities were assayed on fixed cells using the ALP substrate or the leukocyte acid phosphatase reagent, respectively (both from Sigma-Aldrich, St. Louis, MO, USA), according to manufacturer's instructions. Immunofluorescence on cells or muscle cryosections was performed as described previously (20) . The following primary antibodies were used: anti-sarcomeric myosin heavy chains MF20 (21); anti-cardiac troponin I (cTnI; Covance, Princeton, NJ, USA); anti-laminin (Sigma-Aldrich); anti-c-kit (BD Biosciences, San Jose, CA, USA), anti-MyoD (Dako, Glostrup, Denmark); anti-␣sarcoglican (␣-SG; Novocastra, Newcastle upon Tyne, UK). Fluorochrome-labeled secondary antibodies (Sigma) and Hoechst (Fluka, Buchs, Switzerland) for nuclear staining were then used. Samples were examined in a Zeiss Axioskop 2 Plus fluorescence microscope, equipped with a CCD camera.
Flow cytometry analysis
Cells (10 6 ) were incubated on ice with 1 g of the appropriate fluorochrome-labeled antibody and analyzed with a FacsStar Plus cytofluorimeter. The following antibodies were used: anti-Sca-1, -CD45, -c-kit, -CD34, -CD11b, -Gr-1, -Ter-119, and -Mac-3 (BD Biosciences). Nonspecific fluorescent emission was determined with the specific labeled isotype. For cell cycle analysis, cells were stained with propidium iodide.
Intra-arterial transplantation
BpV-treated or untreated GFP-C2C12 cells (5ϫ10 5 ) were injected into the femoral artery of 2-mo-old mice, as described previously (3, 9); ␣-SG null mice (␣SG Ϫ/Ϫ ) were kindly provided by Dr K. P. Campbell (28) . Mice were euthanized at 3, 5, 7, or 21 days after injection; single muscles were dissected and either processed for cryosections or used for RNA preparation. All procedures were conducted in conformity with the institutional guidelines that are in compliance with national and international laws and policies.
Statistical analysis
Statistical analysis was conducted using a t test. The criterion for statistical significance was *P Ͻ 0.05.
RESULTS
BpV treatment reversibly inhibits myogenic differentiation
We first analyzed the effect of BpV treatment on myogenic differentiation. Subclonfluent growing C2C12 cells were placed in DM, with or without 10 M BpV. Within 4 -5 h of treatment, BpV-treated C2C12 cells acquired a round shaped morphology; moreover, many of the cells detached from the dish, without showing any features of degeneration or apoptosis (Fig. 1A) . BpV-treated primary MSC, which are already round shaped, detached from the dish to a similar extent (data not shown). Long-term (48 -72 h) exposure to BpV inhibited the formation of C2C12 and MSC multinucleated myotubes ( Fig. 1A and data not shown). The inhibition of myogenic differentiation was paralleled by a sharp down-regulation of the muscle regulatory factors (MRFs) transcripts (MyoD, myf5, and myogenin) in both C2C12 cells and MSCs; it is noteworthy that to achieve an equivalent MRF down-regulation as in MSCs, C2C12 cells needed to be exposed to BpV for 48 h, suggesting that the inhibition of myogenic differentiation occurs with different kinetics in the two cell populations (Fig. 1B) .
To verify whether BpV-treated cells maintained their myogenic potential, C2C12 cells and MSCs were transferred in DM with or without 10 M BpV; after 24 h, the medium was replaced with fresh DM, cultured for additional 3 days in the absence of BpV, and analyzed for myosin expression by immunofluorescence. Parallel cultures were maintained in DM containing BpV. As shown in Fig. 1C , while no myosin-positive cells were found when the cells were exposed to BpV continuously, both pretreated C2C12 cells and MSCs still differentiated into multinucleated myosin-positive myotubes, upon BpV removal, with a fusion rate only slightly lower than untreated cells.
BpV treatment induces cell cycle progression
Permanent withdrawal from the cell cycle is a prerequisite for myogenic differentiation. To verify whether the BpV-dependent blockade of the myogenic program was associated to changes in the proliferative capacity of myogenic cells, cell cycle was monitored by FACS analysis in BpV-treated, untreated, and proliferating C2C12 cells, cultured for different periods of time ( Fig.  2A-C) . C2C12 cells cultured in BpV-containing DM displayed both a slower decrease in the percentage of cells in the S phase and a slower accumulation in the percentage of cells in the G 1 phase, as compared to untreated cells, even when cultured in GM. Accordingly, RT-PCR analysis demonstrated the up-regulation of both cyclin D1, a marker of the G 1 /S phase transition, and PCNA, a marker of the S phase, in BpVtreated C2C12 cells and MSC, as compared to untreated cells (Fig. 2, D) . 
BpV imposes a phenotype of muscle precursor cells to C2C12 and MSC
To characterize the phenotype acquired by C2C12 cells and MSCs on BpV treatment, we first analyzed by RT-PCR the expression of markers defining the muscle derived stem cells (MDSC; ref. 7) . In contrast to MRFs, the expression of which was down-regulated in response to 24 -48 h BpV treatment (Fig. 1A) , the expression of the MDSC markers Sca-1, Pax-3, and c-met were all sustained both in C2C12 cells and MSCs (Fig. 3A) . Accordingly, the expression of the satellite cell marker Pax 7, which is known to be down-regulated when the cells are induced to differentiate, was also maintained by BpV treatment in both C2C12 and MSCs; however, longer exposure (48 h) led to its down-regulation, in line with the block of the myogenic program (Fig. 3A) . A characteristic shared by most MDSCs is the ability, upon Hoechst 33342 staining, to locate as an SP in the FACS profile, due to the exclusion of the dye through the activity of members of the ABC transporter superfamily [the multidrug resistance-1 (MDR1) and the breast cancer resistance protein (BCRP1)]. As shown in Fig. 3B , untreated C2C12 cells expressed BCRP1, and its expression was not modified by BpV treatment; by contrast, the expression of MDR1a and b, undetectable in untreated cells, was highly up-regulated upon BpV treatment. Untreated MSCs expressed MDR1b at levels that were not further increased by BpV treatment, whereas the expression of MDR1a and BCRP1, undetectable in untreated cells, was highly (Fig. 3B) . The very low percentage (0.02%) of the total C2C12 cell population located in the SP fraction increased 4-to 5-fold (0.11%) in response to BpV treatment. As expected, a higher percentage (0.11%) of untreated MSCs showed the SP phenotype and BpV treatment resulted in a 2-fold increase in the percentage of SP population (0.21%).
BpV induces stem and hematopoietic markers in C2C12 and primary SCs
We next analyzed untreated and BpV-treated C2C12 cells for the expression of stem and hematopoietic surface markers by FACS (Fig. 3C) . We found that, upon 24 h BpV treatment, the stem cell markers Sca-1 and c-kit, already detectable in untreated cells, were significantly up-regulated; the expression of CD34, a marker of hematopoietic stem cells as well as of quiescent SCs, was further increased; the hematopoietic marker CD45 was strongly up-regulated, whereas CD11b, a monocyte/macrophage marker, displayed a modest up-regulation. Finally, the expressions of Mac-3, Gr-1, and Ter119, markers of macrophages, granulocytes, and erythrocytes, respectively, were all up-regulated. Up-regulation of Sca1, Mac3, and CD11b was also detected in BpV-treated MSCs (Fig. 3C) . 
BpV treatment induces multilineage potentiality in C2C12 cells
The gene expression profile acquired by the BpVtreated cells prompted us to evaluate whether BpVtreated cells may acquire multilineage potentiality. We first assessed the ability to generate cells of different hematopoietic lineages. To this aim, C2C12 cells were cultured in the presence or in the absence of 10 M BpV for 24 h and then shifted to myeloid colony assay culture conditions, with or without lower BpV concentration (2 M). After 5 days, although both untreated and BpV-treated cells formed colonies at similar cloning efficiency (2-3%), untreated cells formed clones of adherent cells, while BpV-treated cells formed hematopoietic-like colonies (Fig. 4A) . The hematopoietic-like colonies were harvested to analyze cell morphology and gene expression. As shown in Fig. 4A , many of the cells acquired morphological features typical of myeloid cells such as monocytes, macrophages or granulocytes. Accordingly, RT-PCR analysis showed that harvested BpV-treated cells expressed the granulocyte macrophage colony stimulating factor receptor (GM-CSFR) and the interleukin-3␣ receptor (IL-3R␣), two genes normally expressed in both hematopoietic stem cells (HSCs) and common myeloid progenitors (CMPs; ref.
29; Fig. 4A ). The potential of BpV pretreated cells to generate cells of hematopoietic origin was further confirmed by their ability to acquire an osteoclast-like phenotype, when cultured for 5 days in DM supplemented with 100 nM 1,25(OH) 2 vitamin D3 and 2 M BpV. The acid phosphatase activity (TRAP) histochemical assay showed that Ͼ20% of the BpV-treated cells became TRAP positive (Fig. 4B) . No TRAP-positive cells were detectable in untreated controls. The acquisition of an osteoclast-like phenotype on BpV treatment was also confirmed by the induction of two osteoclast transcripts, microphthalmia transcriptor factor (MFIT; ref. 30 ) and matrix metalloproteinase (MMP9; ref. 31 ; Fig. 4B ).
We next verified whether BpV-treated cells were also capable of differentiating into a cell lineage of mesenchimal origin, such as osteoblasts. C2C12 cells, as well as MSCs, have long been known to have some multipotentiality, including a BMP2 response that can induce bone formation but only by treatment with very high concentrations of BMP2 (100 -300 ng/ml; ref. 32). We tested whether BpV treatment may "prime" the cells to be more responsive to signals generated by the environment, as BMP2 lower concentration. To this purpose, untreated or BpV pretreated C2C12 cells, as above, were cultured for 5 days in DM, supplemented with 50 ng/ml bone morphogenetic protein 2 (BMP2) with or without 2 M BpV. The alkaline phosphatase activity (ALP) hystochemical assay showed that cells treated with only 50 ng/ml of BMP2 were negative for ALP activity; however, ϳ5% of the BpV-treated cells became ALP positive (Fig. 4C) . Osteoblast conversion of BpVtreated cells was confirmed by the induction of the transcripts for the osteoblast markers ALP, osteocalcin, type I collagen as well as the Cbfa1 transcriptor factor, which is considered the osteoblast master gene for its essential role in osteogenesis and osteoblast differentiation (33, 34; Fig. 4C ).
Finally, we tested the ability of BpV-treated cells to acquire a cardiomyocyte-like phenotype. To this purpose, GFP-expressing C2C12 cells, untreated or BpV pretreated, were seeded on a cardiomyocytes monolayer and cultured for additional 4 days, in DM with or without 2 M BpV. As shown in Fig. 4D , none of the BpV-untreated GFP-expressing cells coexpressed cardiac tropononin I (cTnI, used as a cardiac marker), as detected by immunofluorescence, whereas a small proportion (ϳ0.5%) of BpV-treated GFP-expressing cells coexpressed cTnI.
BpV-induced reprogramming of gene expression requires NF-B activation
To understand the contribution of BpV-induced signaling pathway(s) to the observed phenotype, we analyzed AP1 and NF-B activity in BpV-treated muscle cells. Both pathways are known to be induced by BpV (35, 36) and to be strongly down-regulated during myogenic differentiation (16 -17) .
As shown in Fig. 5A , BpV treatment induced a transient activation of AP1 trascriptional activity, which peaked at 6 h, with a concomitant activation of Ser-63 c-jun phosphorylation. Moreover, BpV induced a rapid 2-to 3-fold activation of NF-B-dependent transcription, which peaked by 8 -9 h and remained above the basal activity throughout the 24 h of treatment. TNF-␣, a well-known NF-B activator used as a control, induced a similar 2-to 3-fold induction that decreased below the basal activity within 15 h. Intriguingly, we did not observe IB kinase (IKK) complex-dependent Ser-32-IB␣ phosphorylation nor IB␣ degradation in response to BpV treatment. By immunoprecipitation and subsequent Western blot analysis, we demonstrated that BpV induced both IB␣ tyrosine phosphorylation and p65 nuclear translocation, within 30 min of treatment (Fig. 5A ). Tyr42 phosphorylation of IB␣, followed or not (depending on the cell system) by its proteolitic degradation, has been identified recently as an "alternative" NF-B activation pathway induced by a number of stimuli including the PTPase inhibitor pervanadate (37, 38) .
Next, we sought to verify whether BpV-induced activation of NF-B is required for the observed gene expression. To this aim, C2C12 cells were transfected with the p50⌬SP expression vector, encoding the dominant negative mutant form of the p50 NF-B subunit (24) . This mutant lacks the DNA-binding domain, but it is able to form both homo-and hetero-dimers with the other members of the family (p65 and RelB, as the major subunits expressed in C2C12 cells; ref. 39) , thus functioning as a super-repressor for NF-B activity. A GFP expression vector was also cotransfected (at a 5:1 M ratio p50⌬SP:GFP). The cells were transferred in DM with or without 10 M BpV. After 24 h, the cells were FACS analyzed for the expression of c-kit and Mac3, used as molecular markers of BpV-induced gene ex- pression changes. The expression of the exogenous p50⌬SP was assessed in parallel cultures by Western blot analysis, as its ability to reduce NF-B-dependent gene activation by gene reporter assay (see Supplemental Fig. S1 ). The results showed that the BpV-induced Ͼ2-fold c-kit expression in GFP Ϫ cells was significantly reduced in GFP ϩ ⌬p50-transfected cells (Fig. 5B) ; similarly, p50⌬SP mutant expression prevented the 3-fold Mac3 induction by BpV in the GFP ϩ cell population (Fig. 5B) . Parallel cultures were analyzed for morphology and a significant 40% reduction in cells acquiring round shape morphology was observed (not shown).
BpV-treated muscle cells acquire the phenotype of a circulating progenitor
Finally, we sought to verify whether the gene expression profile and the multipotentiality of BpV-treated cells might also be associated with the acquisition of the phenotype of circulating progenitor, which could be delivered systemically and colonize different tissues. To this purpose, 5 ϫ 10 5 GFP-expressing C2C12 cells, untreated or treated with BpV for 24 h, were injected into the femoralis artery of ␣SG Ϫ/Ϫ mice (3). These mice represent a model for muscular dystrophy, in which degenerating muscle fibers are continuously replaced by muscle cell precursors. Three days after intra-arterial transplantation, very few untreated GFPpositive mono-nucleated cells were observed, restricted within very damaged areas of the skeletal muscle tissue (data not shown). By contrast, when BpV-treated cells were transplanted, a large number of clustered GFPexpressing mononucleated cells were observed, most of which expressed c-Kit (Fig. 6A-C) but not MyoD (not shown). Although with variability among different microscopic fields, hundreds of donor cells could be detected. By day 5, an average of five to six GFP-positive mono-nucleated cells/micro-field were observed, spread throughout the muscle, mostly in the interstitial space (Fig. 6D, G) . By day 7, some of these cells (5-10%) could be detected that now expressed MyoD, indicating the activation of a myogenic differentiation program (Fig. 6E) . By day 21, many fibers (82Ϯ17/ cross sectional area) of the transplanted tibialis anterior (TA) expressed ␣SG (an example is shown in Fig. 6F ). Quantitative RT-PCR analysis showed that a significant recover of ␣SG expression was detectable in the intraarterially transplanted TA (Fig. 6H) . Untreated C2C12 cells did not give rise to ␣SG positive fibers when transplanted intra-arterially (not shown). These results demonstrate that BpV treatment significantly enhances the ability of C2C12 cells to circulate, to cross the vessel wall, and consequently, to contribute to muscle regeneration.
DISCUSSION
In this study, we demonstrated that myogenic cells treated with the PTP inhibitor BpV acquire functional plasticity with the ability, when cultured in the appropriate conditions, to commit toward phenotypes belonging to distinct lineages; to colonize, via arterial circulation, skeletal muscle; and, finally, to contribute to muscle regeneration.
The feasibility of reprogramming gene expression and reverting already committed cells into a pluripotent state by the ectopic expression of specific genes is supported by a number of observations (12, 14, 15, 40) . Cell fate can be changed upon exposure to nuclear and cytoplasmic extracts from cells of different origin (41, 42) or by cell fusion (43) . Certain extracellular signals also exert similar effects: FGF2 induces oligodendrocyte precursor cells to revert to multipotential neural stem cells (44) , whereas the SP subset within C2C12 muscle cells is expanded upon exposure to FGF6 (45) . Differently from models that require the ectopic expression of a given gene, the use of cell surface receptor ligands, or pharmacological compounds can induce a reversible blockade of the differentiation program, thus allowing treated cells to redifferentiate when placed in the right microenvironment.
We show here that BpV-treated myoblasts acquire a round shape morphology and an anchorage-independent phenotype, inhibiting myogenic differentiation. More importantly, BpV-dependent inhibition of differentiation is reversible, as myoblasts (both C2C12 and MSC cells) recover their myogenic potential on removal of the drug. BpV-treated cells do not arrest, nor differentiate, but continue to divide, though cultured in DM. Importantly, longer exposure to 10 M BpV (Ͼ48 -72 h) results, in agreement with its reported anti-neoplastic activity (20) , in cell death. BpV effects on muscle cells proliferation and differentiation can be explained by its ability to prevent the down-regulation of NF-B and AP1 transcriptional activity. Accordingly, cyclin D1 expression, the transcription of which is known to be regulated by NF-B in proliferating myoblasts (17) , is up-regulated in BpV-treated myoblasts cultured in DM. TNF-␣, which interferes with NF-B and AP1 down-regulation, also blocks myogenic differentiation, but its effect is not reversible, possibly due to the concomitant degradation of myogenic transcripts (18) . In addition, BpV-dependent NF-B activation, differently from TNF-␣, involves an alternative activation pathway that is mediated by Tyr42-IB␣ phosphorylation and NF-B subunits nuclear translocation without IB␣ degradation. Further experiments will be needed to precisely define the molecular mechanisms underlying the selectivity of BpV activities in myoblasts and the relative contribution of the BpV-induced signaling pathways. However, according to the results obtained with the p50⌬SP dominant negative mutant, we provide evidence that NF-B signaling and transcription activity are indeed required for BpV-dependent reprogramming of gene expression.
Our results also show that BpV dramatically modifies muscle cells gene expression profile: MRFs are downregulated, whereas Pax7 down-regulation is delayed as the expression of markers defining muscle precursor cells, such as, Pax-3 and c-met. Moreover, BpV treatment induces the expression of markers characteristic of adult mesenchymal or hematopoietic stem cells, such as CD34, Sca-1, and c-kit, as well as of hematopoietic lineages (CD45, CD11b, Mac-3, Gr-1, and Ter-119). Importantly, BpV treatment also induces the expression of a complete set of the ABC transporters and the expansion of the SP in both C2C12 cells and MSC. Whether similar gene expression profile is activated in all the exposed cells or whether different cell subpopulations arise upon BpV treatment, expressing different sets of genes, is not yet clear. Anchorage-independency appears not to reflect a cell selection, in terms of both gene expression and differentiation potential (not shown). However, altogether, the observed gene expression profile suggests that BpV induces a broad reprogramming of gene expression.
Accordingly, BpV-treated C2C12 cells greatly expand their plasticity and acquire the ability to differentiate along multiple lineages (hematopoietic/myeloid, including osteoclast, and cardiomyocyte). Indeed, BpV exposure lowers the BMP2 concentration required for C2C12 cells conversion into osteoblast (24, 35) . Although BpV-promoted plasticity may not have actual applications per se, it strongly supports the conclusion that BpV imposes to the exposed cells the phenotype of precursor cells and "primes" the cells to be more responsive to signals generated by the environment. The ability to circulate, to migrate across the endothelium, and to colonize different tissues (i.e., the acquisition of a circulating progenitor phenotype) would certainly represent an highly desirable property in the perspective of developing innovative cell therapy strategies.
The results reported in this study demonstrate that, when injected systemically, BpV-treated C2C12 cells, are able to migrate outside the vessels in the presence of inflammation, as in the case of dystrophic muscle; to reach muscle tissue, with a much higher efficiency than untreated cells; and, more importantly, to contribute to muscle repair. Thus, BpV imposes to C2C12 cells the phenotype of circulating precursors, increasing their homing toward the dystrophic muscle, while maintaining their myogenic potential, because of the reversibility of the effect. It is noteworthy that the reversion to the myogenic phenotype of BpV-treated cells delivered by intra-arterial injections occurs much slower in vivo than in vitro, as demonstrated by the persistent expression of c-Kit and the late appearance of MyoD. Nevertheless, after 21 days many injected cells had produced ␣SG-expressing fibers.
The mechanism used by transplanted cells to reach muscle tissues is not clear at the moment. An attractive hypothesis would be that BpV treatment induces inflammatory cytokines receptors expression, the transcription of which is regulated by NF-B signaling in many cases, allowing circulating myogenic cells to respond to signals from the inflammatory environment of the dystrophic muscle. Sensitivity to such signals may thus improve homing, but, on the other hand, it may prevent myogenic differentiation, thus explaining the observed in vivo delay in the activation of the myogenic phenotype, as compared to the in vitro results.
In conclusion, the results reported in this study suggest that BpV treatment may represent a valuable approach to generate circulating precursors from committed cells, suitable for gene-cell therapy applications, as well as to study the molecular mechanism leading to genome reprogramming and "stem-ness."
